New York, NY (March 29, 2014) – Amgen (NASDAQ:AMGN) was named a National Multi-Market Corporate Sponsor for the Kidney Walk, the National Kidney Foundation (NKF) announced today.
Through this partnership, Amgen will support 25 Kidney Walk events being held in major cities around the country.
"Working to spread awareness of kidney disease and risk factors together with the National Kidney Foundation is part of Amgen's ongoing commitment to communities and patients across the country," said Daniel Billen, vice president and general manager of Inflammation and Nephrology at Amgen. "We believe that teaming up with the National Kidney Foundation can change the course of kidney disease in the U.S."
The Kidney Walk is the country's largest walk to fight kidney disease. The nationwide series is comprised of more than 80 community events that call attention to kidney disease and the need for organ donation. More than 100,000 walkers, 6,000 teams and 300,000 donors raise more than $8 million dollars annually to support the NKF's local awareness, prevention and treatment programs.
"The Kidney Walk is not only a fundraiser, but a tool to generate awareness and drive prevention in major cities and communities throughout the U.S.," said Krystn Kuckelman, the National Walk Program Director. "Amgen's support will help us reach the millions who are at risk of developing kidney disease."
Each year, kidney disease kills more people than breast and prostate cancer combined. One in three American adults – 73 million – is at risk due to high blood pressure, diabetes or a family history of kidney failure. More than 26 million people in the U.S. already have kidney disease and most don't know it.
"The NKF is on the front lines when it comes to raising awareness of kidney disease and advocating for kidney patients," said Billen. "We are proud to partner with the NKF to empower those at risk to take a lifesaving step, whether that means supporting the cause by joining a Kidney Walk, or scheduling a visit to the doctor to get tested if they are at risk."
- More than 26 Million Americans - 1 in 9 adults – have chronic kidney disease and most don't know it.
- 73 million American adults are at risk due to high blood pressure, diabetes, age over 60 or a family history of kidney failure.
- More than 415,000 people in the United States depend on dialysis treatment to survive.
- More than 99,000 Americans currently await a life-saving kidney and 13 will die each day while waiting.
The National Kidney Foundation is the leading organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk. For more information, visit www.kidney.org.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.